Butler, Rebecca, Smith, Nichola and Hunt, Thomas (2015) ENaC Inhibitors for the Treatment of Cystic Fibrosis. Pharmaceutical Patent Analysis.

Abstract

The epithelial Na+ channel, ENaC, is a key regulator of the volume of airway surface liquid (ASL) in the human airway epithelium. In Cystic Fibrosis (CF), Na+ hyperabsorption through ENaC, in the absence of CFTR-mediated anion secretion, results in the dehydration of respiratory secretions and the impairment of mucociliary clearance (MCC). The hypothesis of utilising an ENaC blocking molecule to facilitate restoration of the ASL volume, sufficiently to allow normal MCC is of interest in the management of lung disease in CF patients. This review summarizes the published patent applications from 2010 that claim approaches to inhibit the function of ENaC for utility in the treatment of CF. Patents were located though SciFinder, using “ENaC” as the key word from 2010, documents not relevant to CF were then manually removed.

Item Type:	Article
Date Deposited:	29 Apr 2016 23:45
Last Modified:	29 Apr 2016 23:45
URI:	https://oak.novartis.com/id/eprint/22575